|
Symposium
[Free Online] The Science and Stories of Promising Biotech Startups
Speakers:
Richard Yu, Abalone Bio; Steve Wood, Neuron23; William Shrader, AcureX Biosciences; Li-Fen Lee, Apeximmune; Nancy Pryer, Ambagon Therapeutics; Maya Skubatch, Wilson Sonsini, Michael Weickert, Fe Pharmaceuticals
Organizers:
Toby Freedman (Synapsis Search); Sarah Bodary (AbCellera); Donald McCarthy (Samsara BioCapital); Shichang Miao (PBSS)
Date:
2024-02-22
Time:
8:30-13:00 Pacific Time
Registration fee:
0
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-02-21
(it will close sooner if the seating cap is reached)
About the Topic
This symposium series aims to provide a platform for promising biotech startup companies to highlight their science and share their stories in building a fledgling business. About the Speakers
Time (PT) |
Topic |
Speaker |
8:30-8:40 am |
PBSS Welcome |
Shichang Miao, PhD, PBSS |
8:40-9:15 am |
Discovery of a Novel Immune Attenuating Target of the Tumor Microenvironment for Cancer Immunotherapy |
Li-Fen Lee, PhD, CEO, Apeximmune |
9:15-9:50 am |
Forging New Paths in Parkinson’s Disease Drug Development |
William D. Shrader, PhD, CEO, AcureX Therapeutics |
9:50-10:25 am |
Neuron23: The Path to Precision Neurology |
Steve Wood, PhD, Executive VP Drug Discovery, Neuron23 |
10:25-10:35 am |
Break |
- |
10:35-11:10 am |
IP Strategies to Protect ADC Assets |
Maya Skubatch, JD, Partner, Wilson Sonsini |
11:10-11:45 am |
From Discovery to Design of Functional Antibody Drugs |
Richard Yu, PhD, CEO, Abalone Bio |
11:45-12:20 pm |
Dealing with Antibiotic Resistance by Starving Pathogens for Iron |
Michael Weickert, PhD, CEO, Fe Pharamceuticals |
12:20-12:55 pm |
Building Ambagon Therapeutics, a Small Molecular Molecular Glue Platform Company |
Nancy Pryer, PhD, CSO, Ambagon Therapeutics |
12:55-1:25 pm |
Q&A and Symposium Conclusion |
All Speakers |
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: Untangling What We Thought We Knew and Future Precision Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro Delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Submit a Text Ad
|